Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Oleg A. Levada
Observed names:
O A Levada,
O. A. Levada,
O. Levada,
O. V. Levada,
O.A. Levada,
Oleg Levada,
О. А. Левада
show all 7
Institutions:
Zaporizhzhia State Medical and Pharmaceutical University,
European College of Neuropsychopharmacology,
European Psychiatric Association
Observed institutions:
Zaporizhzhia Medical Academy of Post-Graduate Education Ministry of Health of Ukraine,
Zaporizhzhia State Medical and Pharmaceutical University,
European College of Neuropsychopharmacology,
European Psychiatric Association
ORCID:
0000-0002-4113-8706
Observed ORCID:
0000-0002-4113-8706
OpenAlex ID:
A5089437506
Poststroke Depression Biomarkers: A Narrative Review
2018
·
Oleg A. Levada
, Alexandra S. Troyan
·
Frontiers in Neurology
·
101
PDF
Insulin-like growth factor-1: a possible marker for emotional and cognitive disturbances, and treatment effectiveness in major depressive disorder
2017
·
Oleg A. Levada
, Alexandra S. Troyan
·
Annals of General Psychiatry
·
53
PDF
Cognitive-functional relationships in major depressive disorder: Crucial data from a Ukrainian open-label study of vortioxetine versus escitalopram
2019
·
Oleg A. Levada
, Alexandra S. Troyan
·
Journal of Affective Disorders
·
37
Plasma Brain-Derived Neurotrophic Factor as a Biomarker for the Main Types of Mild Neurocognitive Disorders and Treatment Efficacy: A Preliminary Study
2016
·
Oleg A. Levada
, Nataliya V. Cherednichenko
, et al.
·
Disease Markers
·
30
PDF
The Diagnostic Value of the Combination of Serum Brain-Derived Neurotrophic Factor and Insulin-Like Growth Factor-1 for Major Depressive Disorder Diagnosis and Treatment Efficacy
2020
·
Alexandra S. Troyan
, Oleg A. Levada
·
Frontiers in Psychiatry
·
26
PDF
Serum insulin-like growth factor-1 as a potential marker for MDD diagnosis, its clinical characteristics, and treatment efficacy validation: data from an open-label vortioxetine study
2020
·
Oleg A. Levada
, Alexandra S. Troyan
, et al.
·
BMC Psychiatry
·
24
PDF
Мозговой нейротрофический фактор BDNF: нейробиология, маркёрное значение в нейропсихиатрии
2015
·
O. A. Levada
, N. V. Cherednichenko
·
Likarska sprava
·
22
PDF
Major depressive disorder and accelerated aging from a peripheral IGF-1 overexpression perspective
2020
·
Oleg A. Levada
, Alexandra S. Troyan
·
Medical Hypotheses
·
12
Neuropsychiatric Symptoms in Patients with the Main Etiological Types of Mild Neurocognitive Disorders: A Hospital-Based Case–Control Study
2017
·
Oleg A. Levada
, Nataliya V. Cherednichenko
, et al.
·
Frontiers in Psychiatry
·
11
PDF
Рівень білка S100В сироватки крові як маркер прогресування легких когнітивних порушень судинної етіології у субкортикальну судинну деменцію та ефективності терапевтичних впливів
2012
·
O. A. Levada
, A. V. Trailin
·
Likarska sprava
·
11
PDF
[Post-stroke depression].
2006
·
O A Levada
, E I Slivko
·
PubMed
·
10
Clinical and neuroimaging aspects of formal thought disorder in schizophrenia: a brief narrative review
2024
·
O. A. Levada
, O. S. Troian
·
Modern medical technology
·
4
[Etiology, clinical variants, diagnosis and treatment tactic of cerebellar infarction].
2003
·
O A Levada
·
PubMed
·
4
Parameters of the P300 Potential in Mild Neurocognitive Disorders of Different Etiologies
2016
·
O. V. Levada
, N. V. Cherednichenko
, et al.
·
Neurophysiology
·
3
[Serum serotonin level in patients with depression and panic attacks].
2006
·
O A Levada
, N V Cherednichenko
, et al.
·
PubMed
·
2
[The weakening of the inhibition of the H-reflex in patients with different sites of a hemispheric stroke].
1998
·
O A Levada
, Ie I Slyvko
·
PubMed
·
2
P.745 Vortioxetine treatment elevates serum BDNF levels in MDD patients along with the improvement of cognitive and emotional characteristics
2020
·
O. Troian
, O. Levada
·
European Neuropsychopharmacology
·
1
Specific Cognitive–Psychopathological Phenotypes in Patients With Early Stages of Subcortical Vascular Neurocognitive Disorders: A Hospital-Based Case–Control Study
2018
·
Oleg A. Levada
, Alexandra S. Troyan
, et al.
·
Journal of Geriatric Psychiatry and Neurology
·
1
Параметры потенциала Р300 на этапах развития субкортикальной сосудистой деменции у лиц пожилого и старческого возраста
2014
·
O. A. Levada
, A. V. Trailin
, et al.
·
Likarska sprava
·
1
PDF
[Neurobiology and modern approaches to the treatment of Alzheimer disease].
2003
·
O A Levada
·
PubMed
·
1
Phenotypic Characteristics of Major Depressive Disorder and Cerebral Gray Matter Abnormalities According to Voxel-based Morphometry Data
2026
·
Oleg Levada
, Oleksandra Troian
, et al.
·
Proceedings of the Shevchenko Scientific Society Medical Sciences
PDF
Decreased PON1 activity as a biological marker for depressive disorders: a narrative review
2025
·
Oleg A. Levada
, Oleksandra S. Troian
·
Journal of Affective Disorders Reports
Depressive Disorders and Their Correction in Patients With Complicated Diabetic Foot Syndrome
2023
·
S. D. Shapoval
, I. L. Savon
, et al.
·
Kharkiv Surgical School
PDF
P.317 Serum insulin-like growth factor-1 levels in patients with major depressive disorder and change after two months` vortioxetine treatment
2020
·
O. Troian
, O. Levada
·
European Neuropsychopharmacology
P.018 Vortioxetine vs escitalopram regarding cognitive and functional recovery in the Ukrainian cohort of patients with major depressive disorder: An 8-week study
2019
·
O. Troian
, O. Levada
·
European Neuropsychopharmacology
Show more works
View as search
Works count:
41
Citation count:
356
H-index:
10
I10-index:
11
Year
Topic
Type